- Fosun International (FOSUY, Financial) aims to achieve carbon neutrality by 2050.
- The company secured a USD 888 million sustainability-linked syndicated loan in 2024.
- Fosun's anticancer drug HANSIZHUANG received EU approval for small cell lung cancer treatment.
Fosun International Limited (FOSUY) has released its 2024 ESG Report alongside its third Climate Information Disclosures Report, underscoring its strong commitment to sustainable development. The company's initiatives align with the global goals of reducing carbon emissions and achieving carbon neutrality by 2050. Fosun's dedication to sustainability is reflected in its maintenance of an MSCI ESG rating of AA and ranking in the top 5% among global peers in S&P Global's Corporate Sustainability Assessment.
In 2024, Fosun achieved a significant milestone by completing a USD 888 million sustainability-linked syndicated loan, marking its prominence among Chinese private enterprises. Additionally, the Bund Finance Center in Shanghai maintained its esteemed LEED Platinum certification, emphasizing the company's commitment to sustainable infrastructure.
Fosun (FOSUY, Financial) continues to propel healthcare innovations, with its anticancer drug HANSIZHUANG receiving approval from the European Union for the treatment of small cell lung cancer. Furthermore, over 80 million severe malaria patients worldwide have benefited from Fosun's artesunate injection. By the end of December 2024, Fosun International’s total assets reached RMB 796.5 billion.
